Top Page
CVS Group plc
(LSE:CVSG)
CVS Group plc (CVSG) vs. iShares MSCI United Kingdom ETF (EWC)
CVS Group plc Business Overview & Revenue Model
CVS Group plc Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 659.20M | 647.30M | 608.30M | 554.20M | 510.10M | 427.80M | Gross Profit |
| 259.70M | 277.90M | 262.30M | 239.10M | 221.90M | 170.10M | EBIT |
| 69.60M | 50.80M | 62.30M | 42.80M | 40.10M | 18.50M | EBITDA |
| 112.50M | 108.40M | 118.80M | 90.40M | 88.20M | 64.90M | Net Income Common Stockholders |
| 17.30M | 6.20M | 41.90M | 25.70M | 19.30M | 5.70M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 11.60M | 16.50M | 21.50M | 49.00M | 33.70M | 21.50M | Total Assets |
| 696.20M | 690.00M | 572.30M | 518.20M | 484.50M | 464.30M | Total Debt |
| 295.50M | 287.80M | 199.10M | 188.80M | 182.70M | 182.20M | Net Debt |
| 283.90M | 271.30M | 177.60M | 139.80M | 149.00M | 160.70M | Total Liabilities |
| 434.80M | 429.50M | 315.30M | 300.80M | 293.40M | 297.70M | Stockholders Equity |
| 261.30M | 260.40M | 257.00M | 217.40M | 191.10M | 166.60M |
| Cash Flow | Free Cash Flow | ||||
| 29.30M | 24.70M | 38.80M | 51.00M | 43.60M | 65.20M | Operating Cash Flow |
| 66.70M | 67.80M | 84.50M | 75.50M | 60.20M | 77.60M | Investing Cash Flow |
| -100.40M | -140.50M | -99.90M | -45.10M | -35.40M | -19.60M | Financing Cash Flow |
| 13.50M | 68.30M | -12.10M | -15.10M | -12.60M | -49.00M |
CVS Group plc Technical Analysis
CVS Group plc Peers Comparison
CVS Group plc Corporate Events
CVS Group plc has responded to the Competition and Markets Authority’s (CMA) decision to extend the deadline for its market investigation into the supply of veterinary services for household pets in the UK. CVS is actively engaging with the CMA, providing feedback on transparency measures and expressing concerns over potential constraints on clinical freedom. The company supports the CMA’s focus on transparency but cautions against remedies that could inadvertently affect animal welfare and consumer choice. CVS remains optimistic that the extension will lead to a more proportionate remedy package, while acknowledging the uncertainty it brings to stakeholders.
The most recent analyst rating on (GB:CVSG) stock is a Buy with a £1500.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc announced that David Wilton, the Non-executive Chairman, has purchased 1,000 ordinary shares in the company, increasing his total shareholding to 10,000 shares, which represents 0.014% of the company’s total voting rights. This transaction, conducted on the London Stock Exchange, signifies a potential vote of confidence in the company’s future prospects by its leadership.
The most recent analyst rating on (GB:CVSG) stock is a Buy with a £1500.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a leading veterinary services provider, announced that its total issued share capital consists of 71,740,184 Ordinary Shares, each carrying one voting right, as of May 30, 2025. This update is crucial for shareholders to determine their interests in accordance with the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:CVSG) stock is a Buy with a £1500.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has finalized the sale of its Crematoria operations to Anima Care UK Limited for £42.4 million, marking a strategic move to streamline its operations. This disposal is expected to result in a one-off profit of £32.0 million in its FY2025 accounts. Concurrently, CVS has expanded its presence in Australia by acquiring VPP Group PTY Ltd, adding six practice sites in Victoria, and now operates 28 practices across 42 sites in the country. These strategic decisions are likely to enhance CVS’s market positioning and operational focus.
The most recent analyst rating on (GB:CVSG) stock is a Buy with a £1500.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has announced a change in its voting rights structure, with BlackRock, Inc. acquiring a significant stake. The notification indicates that BlackRock’s voting rights in CVS Group have increased to 5.02%, crossing the 5% threshold, which is a notable development for the company’s shareholder composition.
CVS Group plc, a leading UK veterinary services provider, announced that its total issued share capital consists of 71,740,184 ordinary shares, each carrying one voting right. This information is essential for shareholders to calculate their interests under the FCA’s Disclosure Guidance and Transparency Rules, indicating the company’s commitment to transparency and regulatory compliance.
CVS Group plc has announced the disposal of its Crematoria operations to Anima Care UK Limited for £42.4 million, aligning with its strategy to focus on core veterinary and diagnostic services. The divestment, representing a 10x multiple of adjusted EBITDA, will enable CVS to reinvest in its UK and Australian operations, enhancing its growth potential while maintaining a leverage ratio below 2.0x. This strategic move is expected to be value accretive, allowing CVS to concentrate on its primary services while still providing comprehensive client care.
CVS Group plc, a leading UK veterinary services provider, announced its total issued share capital as of 31 March 2025, consisting of 71,740,184 Ordinary Shares, each carrying one voting right. This update is significant for shareholders as it affects the calculations for notifying changes in their interests under the FCA’s rules, impacting the company’s transparency and governance.
CVS Group plc announced a transaction involving a ‘Bed and ISA’ transfer of 305 ordinary shares by a person closely associated with Richard Gray, a Non-executive Director. This transaction does not alter Richard Gray’s total interest in the company, which remains at 7,600 shares, representing 0.011% of the total voting rights. The announcement highlights compliance with UK Market Abuse Regulation, ensuring transparency in managerial dealings.